Transforming the prostatic tumor microenvironment with oncolytic virotherapy

Area of Science:

• Oncology
• Immunotherapy
• Virology

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men globally.
• Novel treatment strategies are urgently needed for advanced PCa.
• Oncolytic viruses offer a promising therapeutic avenue.

Purpose of the Study:

• To evaluate the efficacy of an oncolytic immunotherapeutic strategy for prostate cancer.
• To assess the anti-tumor immune response generated by MG1-Maraba virus expressing STEAP.
• To determine the therapeutic potential of this approach in preclinical models.

Main Methods:

• MG1-Maraba oncolytic virus engineered to express the human six-transmembrane antigen of the prostate (STEAP) protein.
• Administration of a priming vaccine and intravenous MG1-Maraba in TRAMP-C2 tumor-bearing mice.
• Analysis of tumor progression, immune cell infiltration, and molecular markers.

Main Results:

• MG1-Maraba demonstrated potent oncolytic activity against PCa cell lines and primary biopsies.
• The oncolytic STEAP immunotherapy induced specific CD8+ T-cell responses and breached immune tolerance.
• Treatment significantly delayed tumor progression, increased intratumoral lymphocytic infiltration, and upregulated MHC class I.

Conclusions:

• Preclinical data support the clinical evaluation of oncolytic STEAP immunotherapy for advanced prostate cancer.
• This strategy shows potential for generating robust anti-tumor immunity.
• Further research is warranted to translate these findings into clinical practice.